U.S.-sponsored trial of new drug regimen to treat tuberculous meningitis starts

LOS ANGELES, Dec. 7 (Xinhua) -- A trial of a new drug regimen to treat tuberculous meningitis (TBM) has started enrolling adults and adolescents in several countries where tuberculosis is prevalent, the U.S. National Institutes of Health (NIH) said on Thursday.

The trial, sponsored by the NIH, will compare a six-month regimen of four drugs with the nine-month, standard-of-care regimen for TBM.